Unlocking New Research Frontiers with Ultra-Sensitive Epigenomics
On-Demand Webinar -- By using a novel in situ strategy that enables unprecedented mapping sensitivity and simplified workflows, CUT&RUN and CUT&Tag are creating a paradigm shift in epigenomics research. Andrea Johnstone, PhD, senior director for product development at EpiCypher, illustrates how these scalable technologies unlock the full potential of epigenomics for next-generation chromatin studies. Read More
Learning from older drug modalities accelerates viral process development
Andrew Tustian, EngD, director of viral process development at Regeneron Pharmaceuticals, spoke with ScienceBoard.net about accelerating process development for adeno-associated viruses by modifying strategies from older modalities. Read More
How one company aims to make bedside cell therapies a reality
SQZ Biotech is developing high-throughput technology that can manufacture novel cell therapy products in under 24 hours. Founder and CEO Armon Sharei, PhD, spoke with ScienceBoard.net recently at Biotech Week Boston 2021. Read More
End-to-end automation of closed manufacturing can make cell therapies more accessible
BOSTON - Cellares is building a cell manufacturing platform that fully automates and closes the process, according to co-founder and CEO Fabian Gerlinghaus. ScienceBoard.net spoke with Gerlinghaus following a presentation at the Cell and Gene Manufacturing and Commercialization event, which is part of Biotech Week Boston 2021. Read More
New tools are needed for next-gen gene therapies
BOSTON - Delivering next-generation viral vectors for use in gene therapies requires that scientists reenvision the tools and process modalities that could be leveraged to make gene therapy a reality, according to Stefano Menegatti, PhD, associate professor at North Carolina State University. Menegatti spoke with ScienceBoard.net during the BioProcess International conference in Boston. Read More
Biotech Week Boston highlights research progress in cell and gene therapy
At Biotech Week Boston, ScienceBoard.net Editor-in-Chief Samantha Black, PhD, spoke with experts in cell and gene therapy technologies. Read More
Future of small-molecule drugs lies in oral formulations
The way forward for small-molecule drug manufacturers is through orally administered products, according to Spiro Rombotis, president and CEO of Cyclacel, who recently spoke with ScienceBoard.net. Read More
Mentors are essential to career journeys
Regardless of your current professional status, supportive mentors are critical for helping you achieve your career goals, according to Michael Howell, PhD, chief scientific officer at DermTech. Howell recently spoke with ScienceBoard.net. Read More
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic is breaking into the world of autologous immuno-oncology therapies. The company's goal is to eventually become a prominent European pharmaceutical firm, according to Radek Špíšek, PhD, CEO and founding scientist of Sotio, who spoke with ScienceBoard.net in a recent interview. Read More
How spatial biology can impact clinical translational research
Building on the success of single-cell technologies, 10X Genomics' Michael Schnall-Levin, PhD, discusses with ScienceBoard.net how the company entered the spatial biology field and how it continues to support the advancement of various clinical translational research efforts. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
